Revenue Increased 12% Year-Over-Year Record Non-Prostate Brachytherapy Revenue Increased 28% Year-Over-Year RICHLAND, WASHINGTON – November 10, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering...
RICHLAND, Wash, April 18, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological...
Fourth Consecutive Quarter of Year-Over-Year Revenue Increases RICHLAND, Wash., Feb. 08, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE American:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment...
Study Demonstrates “Resection Cavity Contractions Affects Cs-131 Dose Distribution Significantly Less than that of I-125 for Permanent Brain Implants” RICHLAND, Wash., Feb. 08, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE American: ISR), a medical technology company...
RICHLAND, Jan. 31, 2018 (GLOBE NEWSWIRE) -- - IsoRay, Inc. (the “Company”) (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and...
Revenue Increase Driven by Increasing Traction of New Sales Strategies in Prostate Brachytherapy RICHLAND, Wash, Jan. 24, 2018 (GLOBE NEWSWIRE) -- -- IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical...
Possible Evidence of Paradigm Shift in the Radiation Treatment of Cancers Afflicting the Brain RICHLAND, Wash.,, Jan. 09, 2018 (GLOBE NEWSWIRE) -- -- IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical...
10 Year Exclusive Agreement to Supply Proprietary Cesium-131 Seeds Embedded in Collagen Tiles RICHLAND, Wash., Jan. 08, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope...
Revenue of $1.21 Million, 12% First Quarter-Over-First Quarter Increase, Gross Margin of 22% RICHLAND, Wash., Nov. 14, 2017 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope...
Potential New Application for Cesium-131 for Unmet Medical Need RICHLAND, Wash., Nov. 09, 2017 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of...
Gross Margin Expands to 36% on Continued Process Improvements and Expense Reduction RICHLAND, Wash., Sept. 28, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for...
Study Demonstrates Ability to Control Local Disease Over Reasonably Long Period of Time, A Major Step in Preserving Quality of Life RICHLAND, Wash., Sept. 26, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed...
9 Year Study Demonstrates Durable Positive Outcomes and Statistically Identical Results of Cesium-131 RICHLAND, Wash., Sept. 25, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical...